Previous 10 | Next 10 |
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
2023-11-05 17:35:55 ET Major earnings expected after the bell on Monday include: Realty Income Corporation ( O ) Vertex Pharmaceuticals Incorporated ( VRTX ) NXP Semiconductors N.V. ( NXPI ) Alteryx ( AYX ) Tanger Factory Outlet Centers ( SKT ) ...
2023-11-03 18:57:50 ET Summary Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration...
2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...
2023-11-03 10:02:39 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Cellectis, VYNE Therapeutics among healthcare movers
2023-11-03 08:22:27 ET More on pre-market losers stock Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Acurx Pharma falls after mid-stage data for lead asset AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio ...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary res...
2023-11-02 10:00:21 ET DENVER, Colo., Nov. 2, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Palantir Technologies Inc (NYSE: PLTR), Panbela Therapeutics Inc (NASDAQ: PBLA), Joby Aviation Inc (NYSE: JOBY...
2023-11-02 08:40:17 ET OmniLit Acquisition ( OLIT ) +75% . Cellectis ( CLLS ) +20% . Shopify ( SHOP ) +18% soars after key metrics come in strong ahead of holiday quarter. Fastly ( FSLY ) +18% Q3 earnings call release Roku ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...